Johnson & Johnson to Settle Remicade Antitrust Lawsuit for $25 Million

Johnson & Johnson (J&J) has reportedly agreed to pay $25 million to settle a lawsuit over an alleged antitrust scheme involving its blockbuster immunosuppressive drug Remicade (infliximab).

The settlement, filed in a federal court in the Eastern District of Pennsylvania, is intended to resolve class-action claims against the company for its alleged obstruction of insurers covering generic versions of Remicade, which is a tumor necrosis-factor blocking drug.

Remicade, which gained initial FDA approval in 1998, is currently approved for multiple indications, including Crohn’s disease and ulcerative colitis. The drug earned more than $3 billion worldwide for J&J in 2021.